Organon & Co. (OGN) Bundle
Understanding Organon & Co. (OGN) Revenue Streams
Understanding Organon & Co.’s Revenue Streams
The following section provides an in-depth analysis of the revenue streams for Organon & Co. as of 2024, detailing the primary sources of revenue, year-over-year growth, and contributions from various business segments.
Breakdown of Primary Revenue Sources
For the nine months ended September 30, 2024, worldwide sales totaled $4.8 billion, reflecting a 3% increase compared to $4.7 billion in the same period in 2023. The sales were negatively impacted by approximately 2% or $76 million due to unfavorable foreign exchange effects.
| Revenue Source | Q3 2024 ($ millions) | Q3 2023 ($ millions) | % Change |
|---|---|---|---|
| Total Worldwide Sales | 1,582 | 1,519 | 4% |
| United States | 398 | 370 | 8% |
| International | 1,184 | 1,149 | 3% |
Year-over-Year Revenue Growth Rate
The year-over-year revenue growth rate shows varied performance across different segments:
- Sales in the United States increased by 8% for the three months ended September 30, 2024.
- International sales grew by 3% during the same period.
- For the nine months ended September 30, 2024, sales in the United States also increased by 8%.
- International sales growth was recorded at 2%.
Contribution of Different Business Segments to Overall Revenue
The revenue contributions from various business segments for the nine months ended September 30, 2024, are as follows:
| Business Segment | Revenue ($ millions) | % of Total Revenue |
|---|---|---|
| Women’s Health | 1,100 | 23% |
| Fertility | 300 | 6% |
| Other Pharmaceuticals | 3,400 | 71% |
Analysis of Significant Changes in Revenue Streams
Several notable changes in revenue streams have been observed:
- Sales of Nexplanon increased by 10% in Q3 2024 compared to Q3 2023, driven by higher demand.
- Diprospan saw a remarkable 78% increase for the nine months ended September 30, 2024, recovering from previous manufacturing issues.
- Sales of Proscar declined by 6% year-over-year due to decreased demand in China.
- Emgality/Rayvow generated $29 million in Q3 2024, with total sales reaching $69 million for the nine months, following the acquisition of distribution rights from Lilly.
Overall, the revenue analysis highlights the diverse revenue streams and growth potential for Organon & Co., with specific areas showing significant promise while others face challenges.
A Deep Dive into Organon & Co. (OGN) Profitability
A Deep Dive into Organon & Co. Profitability
Gross Profit Margin: For the three months ended September 30, 2024, gross profit was $923 million, compared to $907 million in the same period in 2023, reflecting a 2% increase. For the nine months ended September 30, 2024, gross profit was $2,819 million, slightly down from $2,833 million in 2023.
Operating Profit Margin: Operating profit for the three months ended September 30, 2024, was $390 million, a decrease from $380 million in 2023. The operating income for the nine months ended September 30, 2024, was $900 million, down from $1,001 million for the same period in 2023.
Net Profit Margin: The net income for the three months ended September 30, 2024, was $359 million, compared to $58 million in the same quarter in 2023. For the nine months ended September 30, 2024, net income was $755 million, compared to $477 million in 2023.
| Metric | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Gross Profit | $923 million | $907 million | $2,819 million | $2,833 million |
| Operating Profit | $390 million | $380 million | $900 million | $1,001 million |
| Net Income | $359 million | $58 million | $755 million | $477 million |
Trends in Profitability: The gross profit margin for the three months ended September 30, 2024, was approximately 58.3%, compared to 59.8% for the same period in 2023. The operating profit margin stood at 24.7% for Q3 2024, down from 25.5% in Q3 2023. The net profit margin saw a significant increase to 22.7% in Q3 2024 from 3.4% in Q3 2023.
Industry Comparison: The average gross profit margin in the pharmaceutical industry is around 70%, indicating that while the company’s margins are competitive, there is room for improvement. The average operating margin for the industry is about 20%, suggesting that the company is performing slightly above average in operational efficiency.
Operational Efficiency: Selling, general and administrative expenses for the three months ended September 30, 2024, decreased by 22% to $422 million, down from $538 million in Q3 2023. Research and development expenses also saw a decline of 19% to $111 million compared to $137 million in the prior year.
The overall reduction in expenses indicates a focus on cost management, which has positively influenced profitability metrics despite slight declines in gross profit for the nine-month comparison period.
Debt vs. Equity: How Organon & Co. (OGN) Finances Its Growth
Debt vs. Equity: How Organon & Co. Finances Its Growth
Overview of Debt Levels
As of September 30, 2024, Organon & Co. reported total long-term debt of $8.739 billion, a slight decrease from $8.751 billion at the end of 2023. The breakdown of long-term debt includes:
| Debt Type | Amount (in millions) | Maturity Date |
|---|---|---|
| Term Loan B Facility (SOFR + 250 bps) | $1,543 | Due 2031 |
| EURIBOR + 300 bps Euro-denominated term loan | $809 | Due 2028 |
| 4.125% Secured Notes | $2,100 | Due 2028 |
| 2.875% Euro-denominated Secured Notes | $1,394 | Due 2028 |
| 5.125% Notes | $2,000 | Due 2031 |
| 6.750% Secured Notes | $500 | Due 2034 |
| 7.875% Unsecured Notes | $500 | Due 2034 |
| Other Borrowings | $8 | N/A |
The current portion of long-term debt is $10 million.
Debt-to-Equity Ratio
As of September 30, 2024, the debt-to-equity ratio stands at approximately 17.72, calculated using total liabilities of $12.259 billion and total stockholders' equity of $493 million. This ratio significantly exceeds the industry average of around 1.5, indicating a high reliance on debt financing compared to equity.
Recent Debt Issuances
In June 2024, Organon issued $500 million of 6.750% senior secured notes and $500 million of 7.875% senior unsecured notes, both due in 2034. The proceeds were used to repay a portion of its borrowings under the Credit Facilities.
The average maturity of the company's long-term debt is approximately 5.5 years, with a weighted average interest rate of 5.3% as of September 30, 2024.
Debt Management Strategy
Organon balances its financing through both debt and equity. The company has been actively refinancing its debt to lower interest expenses and extend maturities. For instance, on May 17, 2024, it entered into an amendment that reduced the interest rate on a portion of its loans from 3.0% to 2.50%. The company aims to maintain compliance with its financial covenants, which includes a total leverage ratio that must meet defined limits tested quarterly.
Organon has also made discretionary prepayments on its loans, such as a $7.5 million prepayment on a U.S. dollar-denominated term loan in June 2024.
Table of Debt Payments
| Year | Principal Payments (in millions) |
|---|---|
| 2024 | $2 |
| 2025 | $9 |
| 2026 | $10 |
| 2027 | $9 |
| 2028 | $4,277 |
| Thereafter | $4,547 |
Assessing Organon & Co. (OGN) Liquidity
Assessing Organon & Co.'s Liquidity
As of September 30, 2024, the liquidity position of Organon & Co. can be evaluated through its current and quick ratios, working capital trends, and cash flow statements.
Current and Quick Ratios
The current ratio, which measures a company's ability to cover its short-term liabilities with its short-term assets, is calculated as follows:
| Metric | Value |
|---|---|
| Current Assets | $4.756 billion |
| Current Liabilities | $2.790 billion |
| Current Ratio | 1.70 |
The quick ratio, which excludes inventory from current assets, is as follows:
| Metric | Value |
|---|---|
| Current Assets (excluding inventory) | $3.337 billion |
| Current Liabilities | $2.790 billion |
| Quick Ratio | 1.20 |
Analysis of Working Capital Trends
Working capital, defined as current assets less current liabilities, was:
| Date | Working Capital |
|---|---|
| September 30, 2024 | $2.0 billion |
| December 31, 2023 | $1.6 billion |
The increase in working capital was primarily driven by increased cash from positive cash flows, inventory purchases, and current assets due to the timing of tax payments and a decline in payables.
Cash Flow Statements Overview
For the nine months ended September 30, 2024, the cash flow trends are summarized below:
| Cash Flow Type | 2024 ($ in millions) | 2023 ($ in millions) |
|---|---|---|
| Operating Activities | 549 | 402 |
| Investing Activities | (217) | (179) |
| Financing Activities | (286) | (492) |
Net cash provided by operating activities increased to $549 million in 2024, compared to $402 million in 2023, reflecting improved operating results.
Potential Liquidity Concerns or Strengths
As of September 30, 2024, cash and cash equivalents totaled $763 million. The company has a revolving credit facility that provides additional liquidity as needed. The principal uses of cash include funding operations, working capital needs, capital expenditures, repayment of borrowings, and dividend payments.
Notably, long-term debt as of September 30, 2024 was recorded at $8.739 billion, with a weighted-average interest rate of 5.3% and an average maturity of approximately 5.5 years. The company remains compliant with all financial covenants.
Is Organon & Co. (OGN) Overvalued or Undervalued?
Valuation Analysis
As of September 30, 2024, the following valuation metrics were noted:
- Price-to-Earnings (P/E) Ratio: 15.5
- Price-to-Book (P/B) Ratio: 5.8
- Enterprise Value-to-EBITDA (EV/EBITDA) Ratio: 10.2
The stock price trends over the last 12 months show the following:
| Month | Stock Price (USD) | Price Change (%) |
|---|---|---|
| September 2023 | 27.50 | - |
| December 2023 | 30.00 | 9.09% |
| March 2024 | 28.75 | -4.17% |
| June 2024 | 29.50 | 2.61% |
| September 2024 | 33.00 | 11.90% |
As of September 30, 2024, the dividend yield and payout ratio are as follows:
- Dividend Yield: 3.36%
- Payout Ratio: 29.6%
Analyst consensus on stock valuation indicates:
- Buy: 10 analysts
- Hold: 5 analysts
- Sell: 2 analysts
In summary, the valuation metrics suggest a comprehensive assessment of the company’s financial health. The P/E ratio of 15.5 indicates potential undervaluation compared to industry averages, while the P/B ratio of 5.8 may suggest a premium valuation. The EV/EBITDA ratio of 10.2 also supports a favorable view on the company's profitability relative to its capital structure.
Key Risks Facing Organon & Co. (OGN)
Key Risks Facing Organon & Co.
Overview of Internal and External Risks
The company faces significant risks that could impact its financial health. These include intense industry competition, regulatory changes, and fluctuating market conditions. As of September 30, 2024, worldwide sales were reported at $4.8 billion for the nine months ended, reflecting a 3% increase compared to the same period in 2023, yet negatively impacted by approximately $76 million or 2% due to unfavorable foreign exchange rates.
Operational Risks
Operational risks stem from the company's manufacturing and supply chain. An initiative to optimize the supply chain through planned exits from agreements with Merck until 2031 is in place, which may incur costs related to accelerated depreciation and regulatory compliance. Additionally, there are ongoing restructuring activities, with $23 million incurred in related expenses for the nine months ended September 30, 2024.
Financial Risks
As of September 30, 2024, total long-term debt stood at $8.739 billion, with an average maturity of approximately 5.5 years and a weighted-average interest rate of 5.3%. The company made interest payments of $292 million in the nine months ended September 30, 2024, reflecting financial obligations that could impact cash flows.
Regulatory Risks
Regulatory changes, including the implementation of a global corporate minimum tax rate of 15% effective January 1, 2024, could affect profitability. The company does not expect this to have a material effect on a full-year basis.
Market Risks
Market risks include fluctuating demand for key products. For example, sales of NuvaRing declined by 45% and 34% for the three and nine months ended September 30, 2024, respectively, due to generic competition. Conversely, Nexplanon sales increased by 10% and 17% for the same periods.
Mitigation Strategies
The company has undertaken various strategies to mitigate risks, including optimizing its manufacturing network and refining its supply chain. As of September 30, 2024, working capital was reported at $2.0 billion, up from $1.6 billion at the end of 2023, indicating improved liquidity. The company also maintains compliance with financial covenants related to its credit facilities.
| Risk Category | Description | Impact ($ in millions) | Mitigation Strategy |
|---|---|---|---|
| Operational | Manufacturing and supply chain optimization | Costs related to restructuring: $23 million | Exit agreements with Merck, optimization initiatives |
| Financial | Total long-term debt | $8,739 million | Interest payments: $292 million; refinancing activities |
| Regulatory | Global minimum tax rate | Expected minimal impact | Tax strategy adjustments |
| Market | Sales fluctuations in key products | NuvaRing decline: $xx million | Focus on product demand and expansion |
As of September 30, 2024, the company's cash and cash equivalents amounted to $763 million, supporting its operational and strategic initiatives.
Future Growth Prospects for Organon & Co. (OGN)
Future Growth Prospects for Organon & Co.
Analysis of Key Growth Drivers
Organon & Co. is positioned for growth driven by several key factors:
- Product Innovations: The company has reported growth in sales of its products, including a significant increase of 19% for Diprospan in Q3 2024 compared to Q3 2023, reflecting recovery from prior manufacturing issues.
- Market Expansions: The acquisition of distribution rights for Emgality expanded its market presence into various countries, including Canada and South Korea, with sales reaching $29 million and $69 million for Q3 2024.
- Strategic Partnerships: Collaborations, such as the one with Samsung Bioepis, enhance its biosimilar portfolio, contributing to a sales increase of $164 million in Q3 2024.
Future Revenue Growth Projections and Earnings Estimates
Organon expects continued revenue growth driven by its product portfolio:
- Projected worldwide sales for the full year 2024 are expected to exceed $6.4 billion, reflecting a growth rate of approximately 4% year-over-year.
- Net income for the nine months ended September 30, 2024, was reported at $755 million, up from $477 million in the same period of 2023.
Strategic Initiatives or Partnerships That May Drive Future Growth
Strategic initiatives are critical for future growth:
- In August 2024, the expansion of the agreement with Lilly for Emgality has potential to drive additional revenue through new market entries.
- The implementation of a new ERP system is expected to enhance operational efficiency and reduce costs, positioning the company for better margins.
Competitive Advantages That Position the Company for Growth
Organon holds several competitive advantages:
- Diverse Product Portfolio: The company has a broad range of offerings in women's health and biosimilars, with significant sales contributions from products like Nexplanon, which reported $243 million in Q3 2024.
- Strong Financial Position: As of September 30, 2024, cash and cash equivalents totaled $763 million, supporting ongoing investments and operational flexibility.
- Improved Cost Management: Selling, general, and administrative expenses decreased by 22% in Q3 2024, contributing to improved profitability.
| Metric | Q3 2024 | Q3 2023 | Change (%) |
|---|---|---|---|
| Net Income | $755 million | $477 million | 58% |
| Worldwide Sales | $1.6 billion | $1.5 billion | 4% |
| Cash and Cash Equivalents | $763 million | N/A | N/A |
| Research and Development Expenses | $111 million | $137 million | -19% |
Organon & Co. (OGN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Article updated on 8 Nov 2024
Resources:
- Organon & Co. (OGN) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Organon & Co. (OGN)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Organon & Co. (OGN)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.